# 你、你妈妈和你的狗应该使用 CBD 吗？

> 原文:[https://gizmodo . com/should-you-your-mom and-your-dog-be-use-CBD-1834092614](https://gizmodo.com/should-you-your-mom-and-your-dog-be-using-cbd-1834092614)

它们无处不在——在你的超市里，在连锁药店里，甚至在你当地的宠物店里。大麻二酚 ( CBD) ，大麻的主要成分*不会*让你兴奋的最新非处方健康时尚，催生了看似无穷无尽的新产品和可疑的健康声明。

Watch

围绕 CBD 产品有很多炒作，从它们能够帮助缓解焦虑，**到 [降低痴呆症风险](https://420intel.com/articles/2018/08/30/how-find-best-cbd-dosage-alzheimer%E2%80%99s-disease) 或 [治疗癌症](https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq) 。但是科学对 CBD 的健康益处有什么看法呢？对于给自己买一个 CBD 汉堡或者给你的狗买一些 CBD 零食 T21，你应该有多兴奋呢？**

**首先，有必要澄清 CBD 和大麻所在的美国令人困惑的法律环境。**

**联邦政府通过缉毒机构，在历史上将大麻植物及其加工的所有成分(包括 CBD)归类为附表 1 药物，这意味着它被认为没有公认的法律或医疗用途。但在州一级，大麻的医疗和娱乐用途都有例外。去年 6 月，食品药品监督管理局 [也批准了](https://gizmodo.com/fda-approves-first-drug-made-from-cannabis-1827114755) 一种源自 CBD 的药物 Epidiolex，用于治疗某些类型的癫痫发作。去年 12 月，政府 [通过了](https://www.vox.com/the-goods/2018/12/13/18139678/cbd-industry-hemp-legalization-farm-bill) 农业法案中的一项条款，将当地大麻的销售和种植合法化，这是一种种植的大麻，其 THC 含量低于 0.3%，这是大麻的另一个主要成分，是其特征性高的原因。**

**尽管大麻合法化，中央商务区作为消费品的地位仍然模糊不清。在农业法案通过后不久，食品和药物管理局 [发布](http://If you’ve absentmindedly browsed your supermarket, chain pharmacy, or even local pet shop lately, you’ve probably come across the latest over-the-counter health fad: products rich in cannabidiol, or CBD, the main ingredient of cannabis that won’t make you high.   There’s a lot of hyped claims surrounding these products, from them being able to help with anxiety to cutting down the risk of dementia. But what does the science say about CBD’s health benefits? And just how excited should you be about buying yourself or your dog some CBD treats?  For starters, it’s worth clarifying the confusing legal landscape in the U.S. in which CBD and cannabis exists.   The federal government, via the Drug Enforcement Agency, has historically classified the cannabis plant and all ingredients processed from it, including CBD, as a schedule 1 drug, meaning it’s considered to have no accepted medical use. But exceptions have since been carved out on a state level for both the medical and recreational use of cannabis. Last June, the Food and Drug Administration also approved a drug derived from CBD, Epidiolex, for the treatment of certain types of seizure. And this past December, the government passed a provision in its farm bill that legalized the selling and growing of local hemp, a variety of cannabis grown with less than 0.3 percent of THC, the other major component of cannabis that’s responsible for its characteristic high.  Despite the legalization of hemp, the status of CBD as a consumer product itself remains murky. The FDA issued a notice soon after the farm bill was passed clarifying that it still had the authority to regulate any products with CBD, regardless of their source. The agency also warned that it doesn’t sanction the selling of CBD as a supplement, nor would it stand by if companies marketed their over-the-counter products with any specific health claims. The FDA has since issued warning letters to retailers, usually online, that are marketing these products with any professed health benefits.   The ongoing regulatory morass surrounding cannabis and CBD doesn’t just make things confusing for customers and growers, though, it’s also severely slowed down our scientific knowledge of how THC and CBD—whether in cannabis or alone—can affect the body, according to Ziva Cooper, research director of the Cannabis Research Initiative at the University of California, Los Angeles.   “Based on the animal literature, or what we call preclinical research, it seems that CBD can have a wide range of therapeutic effects, ranging from decreased inflammation to helping with anxiety, pain, or substance use disorders,” Cooper told Gizmodo. “The real issue is that we don’t have very much science translating what we see in animals and laboratories to humans”    That doesn’t mean CBD won’t turn out to be even more useful medically than it’s already proven to be for some people with seizures or chemotherapy symptoms like nausea and loss of appetite. Nor should we automatically discount the experiences of people who say their chronic pain and anxiety has been relieved with pot or products like CBD oil or creams. It just means we’re still on the fringes of understanding CBD’s health effects. And it’s inevitable that some of the rosiest, far-reaching claims about it will evaporate under closer scrutiny.  “What we do know is that certain high doses of CBD—300 to 1000 milligrams—have been shown to be helpful for certain indications, including schizophrenia and severe epilepsy disorders. And there’s a hint that it could help with anxiety as well,” said Cooper, referencing several studies and the Epidiolex approval. Cooper and others are also pursuing research in people that’s testing whether different strains of cannabis (CBD-heavy, THC-heavy, or equally mixed) can reduce pain better than others, as well as the dosage of opioids needed to manage that pain.   Despite this potential, there’s another glaring problem when it comes to the trendy CBD-based products like chocolates you’re likely to see in your checkout aisle, according to Cooper. Even if a certain dosage of CBD could help with your anxiety or sleep, you’re almost certainly never getting that much from these products.   “CBD-infused foods or the solutions you might pick up at dispensaries across the country will probably not contain those therapeutic, 300 to 1000 milligram doses. They’ll probably be a lot lower, like 10, maybe 15 milligrams, and very far from what is likely an effective dose,” she said.   Even if these products were chock full of CBD, the different ways they’re introduced into the body could have a dramatic influence on how we would actually respond it. And scientists are completely in the dark as to how these differences would manifest. “We have no knowledge on how CBD will work using all of these products—the lotions, creams, edibles, suppositories—at least based on rigorous studies,” Cooper added.  Products marketed with CBD have a labeling problem too. A study in 2017, for instance, found that only 30 percent of such products bought online accurately labeled how much CBD they had. Many mislabeled products had more CBD than advertised, which isn’t much of a problem, since there’s no dosage that can gravely harm you. But about a quarter had too little CBD, which would just raise your chances of using a placebo in all but name.  Underlabeling isn’t the only risk with CBD products either. Last year, the Centers for Disease Control and Prevention reported that more than 50 people in Utah was poisoned by fake CBD products that actually contained synthetic cannabinoids. These cannabinoids are used to mimic the psychoactive effects of THC in the body, not CBD, but are more potent and capable of causing serious health problems, including hallucinations.   With that in mind, contaminated CBD products are probably a rare risk. And the legalization of hemp will likely streamline and improve the safety of the CBD market overall, as well as speed along research efforts. The FDA has also said it’s beginning to develop a regulatory pathway that will allow the study and marketing of CBD in food or consumer products without any legal hassles. And states such as Utah are taking things into their hands and creating their own regulatory system for legally selling and accurately labeling CBD products.  The CBD hype train will undoubtedly chug forward, with some financial experts estimating that it’ll become a billion dollar industry by 2020\. But at the end of the day, you’re probably not putting yourself and your loved ones in mortal danger by buying that CBD-loaded cookie or hemp pet supplement (so long as you’re not using them to replace standard medical treatments). If you’re looking to keep your wallet safe from hucksters selling useless CBD products, though, you should probably wait to see how the science turns out.) 通知，澄清它仍然有权监管 CBD 的任何产品，无论其来源如何。该机构还警告说，它不批准销售 CBD 作为补充，也不会袖手旁观，如果公司营销其非处方药品与任何具体的健康主张。FDA 已经向以这种方式宣传这些产品的网上零售商发出警告信。**

**例如，美国食品和药物管理局指出的一个特别惊人的说法是，生物多样性公约可以帮助管理二型糖尿病。但是，尽管对老鼠的研究表明了可能的好处，但唯一一项显然在人类身上进行的研究表明，CBD 在管理实际患者代谢状况的关键方面——血糖水平控制不佳——方面没有做任何事情。**

**这个例子凸显了迄今为止 CBD 研究中最明显的缺陷。我们对它的影响知之甚少，这很大程度上是因为围绕大麻及其副产品的监管困境延缓了研究。我们所知道的一点点往往来自对动物的研究。**

**“根据动物文献，或者我们所说的临床前研究，CBD 似乎可以有广泛的治疗效果，从减少炎症到帮助焦虑，疼痛或物质使用障碍，”加州大学洛杉矶分校大麻研究计划的研究主任 Ziva Cooper 告诉 Gizmodo。“真正的问题是，我们没有太多的科学将我们在动物和实验室中看到的东西转化为人类。”** 

**这并不意味着 CBD 在医学上不会比已经证明的对一些癫痫患者更有用。我们也不应该忽视那些说他们的慢性疼痛或焦虑已经通过大麻或 CBD 油或面霜等产品得到缓解的人的经历。这仅仅意味着我们在理解 CBD 对健康影响的边缘。不可避免的是，一些关于它的最乐观、最深远的主张将在更仔细的审查下消失。**

**“我们所知道的是，某些高剂量的 CBD——300 到 1000 毫克——已被证明对某些适应症有帮助，包括精神分裂症和严重的癫痫症。有迹象表明，它也有助于缓解焦虑，”库珀说，他提到了几项 [研究](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604171/) 和 Epidiolex 的批准。库珀和其他人也在进行人体研究，测试不同品种的大麻(包括主要含有 CBD 的大麻)是否能比其他品种更好地减轻疼痛，以及降低控制疼痛所需的阿片类药物的剂量。**

**“当我告诉公众我正在研究 CBD 治疗疼痛，或作为阿片类药物的替代品时，大多数人会说‘我们不是已经知道了吗？我们不是已经有了这些数据吗？”库珀说但事实是，我们没有。大多数针对 CBD 疼痛的研究也包括 THC。我们对 CBD 本身对人体疼痛的影响知之甚少。"**

**根据库珀的说法，尽管有这种潜力，但当你在收银台看到基于 CBD 的时尚产品时，还有另一个大问题。即使一定剂量的 CBD 可以帮助你缓解焦虑或失眠，你几乎肯定不会从这些产品中获得那么多。**

**“你可能在全国各地的药房买到的 CBD 食品或溶液可能不含 300 至 1000 毫克的治疗剂量。他们可能会低得多，比如 10 毫克，也许 15 毫克，离可能的有效剂量很远，”她说。**

**尽管这些产品充满了 CBD，但它们进入身体的不同方式，如是否食用或涂抹在皮肤上，仍然会对我们如何应对它们产生巨大影响。例如，局部抗生素必须经过特殊配制，才能突破我们皮肤的坚硬层而感染，而鼻腔喷雾剂比舌下含服片剂更快地产生药物效果。科学家们不确定这些差异在 CBD 中会如何体现。**

**“我们不知道使用所有这些产品——乳液、面霜、食品、栓剂 CBD 将如何发挥作用，”库珀说。**

**用 CBD 营销的产品也有标签问题。例如，2017 年的一项研究 [发现](https://jamanetwork.com/journals/jama/fullarticle/2661569) 在网上购买的此类产品中，只有 30%准确标注了它们有多少 CBD。许多贴错标签的产品的 CBD 比宣传的要多，这并不是一个大问题，因为很可能没有剂量会严重伤害你。但是大约四分之一的人 CBD 太少，这基本上意味着你会服用安慰剂。**

**标签不足并不是 CBD 产品的唯一风险。去年，疾病控制和预防中心报道称，犹他州超过 50 人因假冒 CBD 产品中毒，这些产品实际上含有合成大麻素。这些大麻素用于模拟体内四氢大麻酚的精神作用，而不是 CBD，但更有效，能够导致严重的健康问题，包括幻觉和 [精神病发作](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939204/) 。**

**也就是说，受污染的 CBD 产品可能很少。大麻的合法化可能会简化和提高整个 CBD 市场的安全性，并加快研究工作。美国食品和药物管理局还表示，已经开始制定监管途径，允许在没有任何法律纠纷的情况下研究和营销食品或消费品中的 CBD。犹他州等州正在创建自己的监管体系，以合法销售和 [准确标注](https://fox13now.com/2019/01/17/cbd-and-other-hemp-products-must-now-be-registered-with-the-state-of-utah/) CBD 产品。鉴于此，CBD 的炒作列车肯定会突突前进，一些金融专家估计，到 2020 年，它将成为一个价值 [十亿美元的产业](https://www.statista.com/statistics/760498/total-us-cbd-sales/) 。**

**不过，CBD 的科学要赶上这种炒作还需要一些时间。库珀关于 CBD 含量高的大麻可以减少对潜在成瘾阿片类药物的需求的假设可能很快就会被证明，但毫无疑问，人们现在已经在使用 CBD 或大麻来达到确切的目的。虽然 FDA 可能会贬低这种草率，但很难茫然地告诉慢性疼痛患者别无选择，忍气吞声，等待批准的层压密封。**

**只要你不是用它们来完全取代标准的医疗方法，或者完全无视医生的建议，你就不会因为购买含有 CBD 的饼干或大麻宠物补充剂而将自己和你爱的人置于致命的危险之中。但是如果你是一个普通人，想要保护你的钱包不被兜售无用的、新奇的 CBD 产品的小贩偷走，你可能应该等着看科学的结果。**